
Seaport Therapeutics Highlights GlyphAllo™ (SPT-300) Study in Science Translational Medicine
Seaport Therapeutics, Founded by PureTech, Reports Science Translational Medicine Publication Highlighting GlyphAllo™ (SPT-300) as a First-in-Class Triglyceride-Mimetic Prodrug Achieving Therapeutic Drug Levels in Humans PureTech Health plc has highlighted a…












